Shock As AstraZeneca’s Oncology R&D Head José Baselga Dies
AstraZeneca’s CEO Pascal Soriot confirmed the death of distinguished cancer researcher and head of its oncology R&D unit, José Baselga, on 21 March.
You may also be interested in...
The US FDA will now have the full efficacy data that it wanted from AstraZeneca, but the company still has to deal with concerns over safety and global supply issues.
Daiichi Sankyo and AstraZeneca’s ambitions to expand the use of their HER-2 targeted antibody-drug conjugate product beyond breast cancer are looking realizable on the back of new results presented at ASCO, but toxicities remain an issue.
A reorganization at the top of the UK firm brings with it controversial scientist Jose Baselga.